Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study — Axel Le Cesne (2023) | RDL Network
Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
Article 2023 en
Authors
AC
Axel Le Cesne
CC
Christine Chevreau
CP
Christophe Perrin
Abstract
1 min read
This study failed to show any signal of benefit for regorafenib in patients with advanced/metastatic recurrent chordoma.
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi‐Hsiang Huang, G. Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, В. В. Бредер, René Gérolami, Gianluca Masi, Paul J. Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier‐Hourmand, Masatoshi Kudo, Ann‐Lii Cheng, Josep M. Llovet, Richard S. Finn, Marie-Aude LeBerre, ,
Olivier Mir, Sylvain Briand, Thierry Lazure, Julien Adam, Rastilav Bahleda, Jean Yves Blay, Andréa Cavalcanti, Ali N. Chamseddine, Aurélie Dutour, Matthieu Faron, L. Haddag, Clémence Hénon, C. Le Péchoux, Antonin Lévy, Carine Ngo, Benjamin Verret, Charles Honoré, Charles Court, Axel Le Cesne
Nicolas Penel, Antoîne Italiano, Jennifer Wallet, L. Chaigneau, B. Verret, Nelly Firmin, Sarah Watson, Thibaud Valentin, Emmanuelle Bompas, François Bertucci, Mehdi Brahmi, Clémence Hénon, Angélique Brunot, Mariella Spalato Ceruso, Marie Vanseymortier, E Heyman-Decoupigny, Thomas Ryckewaert, Marie‐Cécile Le Deley, Christophe Perrin, Jean Yves Blay
Discussion(0)
No comments yet. Be the first to comment.